

Hepatitis C Treatment Update 12.31.18

Effective December 31, 2018, Jai Medical Systems' preferred treatments for Hepatitis C are Mavyret (for all genotypes) and Zepatier (for genotypes 1 and 4). Jai Medical Systems will continue to use the clinical criteria from Maryland Medicaid when approving treatment, but patients must be ineligible for a preferred treatment before a non-preferred treatment will be approved.

As a reminder, if the member has cirrhosis, the Child Pugh score must be included with any request for Mavyret, Vosevi, Epclusa, or Zepatier. NS5A resistance testing results are required for any requests for Zepatier for a patient with genotype 1a. Treatment Plan forms and Treatment Agreement forms are still required for all requests for Hepatitis C treatment.